MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC 50 of 14.9 nM in kinase assay, an IC 50 of 470 nM in cell assay. Antidiabetic agent In Vitro MAP4K4, a serine/threonine protein kinase may be a viable target for antidiabetic agents. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Oral dosing in telemetered rats for 5 days with MAP4K4-IN-3 (Compound 2; 25 mg/kg, b.i.d.) results in a number of adverse effects. Substantial weight losses (7%) and body temperature increases (0.4°C) relative to controls are observed over the course of the study. For cardiovascular end points, maximal heart rate increases of 25 bpm, relative to controls, are induced by treatment with MAP4K4-IN-3. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:MAP4K4 14.9 nM (IC 50 )
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
MAP4K4-IN-3
CAS number：1811510-58-3 molecular formula：C15H12ClN5
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1811510-58-3 | molecular formula | C15H12ClN5 |
| molecular weight | 297.74 g/mol | Exact mass | ≥99% |
| PSA | 90.700 Ų | logp | 2.300 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
